Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Spruce Biosciences Inc
SPRB | US
54.37
USD0.36
0.67%
SPRB | US
About Spruce Biosciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
54.37
Open
53.64
High
55.90
Low
53.64
Spruce Biosciences Inc. a biopharmaceutical company focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH) which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research develop and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop manufacture and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences Inc. was incorporated in 2014 and is headquartered in South San Francisco California.
View LessSPRB | US
Risk
123.3
Sharpe
0.32
Luna's Score
45/100
Recommendation
Sell
Luna says (SPRB | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
135.9%1 month
123.3%3 months
107.6%6 months
104.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.36
Debt to equity
0.06
Debt to assets
0.05
Ent. to EBITDA
-0.23
Ent. to rev.
15.32
PEG
-
Other Fundamentals
EBITDA
-47.43M
MarketCap
2.25B
MarketCap(USD)
2.25B
Div. yield
-
Op. margin
-623.35
Erngs. growth
-
Rev. growth
-25.60
Ret. on equity
-55.37
Short ratio
0.88
Short perc.
0.92
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
22.64
Range1M
28.64
Range3M
38.87
Volumes: Market Activity
Rel. volume
0.64
Price X volume
3.19M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.23 | - | Cheaper |
| Ent. to Revenue | 15.32 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.36 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 107.58 | - | Riskier |
| Debt to Equity | 0.06 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 2.25B | - | Emerging |
